Bicycle Therapeutics PLC Sponsored ADR BCYC
3.69
(0.04)
(1.07%)
as of 25 Sep
- Market cap
- $199.4M
- P/E
- 0.0×
Follow BCYC
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
18.93 | 6.76 | 5.09 | 4.84 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(7.54) | (25.35) | (4.90) | (5.97) | |
P/B ratio |
0.87 | 0.80 | 0.58 | 0.58 | |
Price to Tangible BV |
0.87 | 0.80 | 0.58 | 0.58 | |
EV/Sales |
(3.21) | (1.61) | (3.39) | (3.15) | |
EV/EBITDA |
0.32 | 0.48 | 0.91 | 0.94 | |
EV/Operating CF |
0.38 | 0.47 | 0.94 | 0.94 | |
EV/FCF |
0.38 | 0.46 | 0.93 | 0.93 | |
Quick Ratio |
10.33 | 11.65 | 12.28 | 11.70 | |
Current Ratio |
10.66 | 11.98 | 12.66 | 12.08 | |
Net Debt/EBITDA |
10.16 | 26.87 | 8.69 | 9.54 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.03 | 0.09 | 0.08 | 0.09 | |
Operating CF/Net income |
1.20 | 0.96 | 1.08 | 0.99 | |
Capex/Depreciation |
(0.38) | (0.43) | (0.63) | (0.25) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
497.92% | 107.96% | 5,513.08% | 6,543.72% | |
Selling, General and Administrative Expense of Revenue |
160.72% | 43.57% | 1,969.33% | 2,230.21% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
74.75% | 24.30% | 781.29% | 1,018.12% | |
Graham Net Nets |
1.11 | 1.17 | 1.61 | 1.62 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(46.77%) | (44.63%) | (67.89%) | (64.39%) | |
Free Cash Flow Yield |
(45.09%) | (51.38%) | (71.66%) | (70.37%) | |
Revenue per Share |
0.17 | 0.69 | 0.01 | 0.01 | |
Operating CF per Share |
(1.03) | (0.28) | (0.95) | (0.71) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | 0.00 | |
Free Cash Flow per Share |
(1.04) | (0.29) | (0.96) | (0.71) | |
Cash per Share |
9.35 | 9.07 | 8.03 | 7.31 | |
Shareholders Equity per Share |
8.92 | 8.80 | 7.95 | 7.31 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.92 | 8.80 | 7.95 | 7.31 | |
Free Cash Flow |
(71.85) | (19.92) | (66.64) | (49.87) | |
Working Capital |
669.54 | 625.90 | 570.25 | 527.60 | |
Capital Expenditures |
(0.67) | (0.57) | (0.71) | (0.26) | |
Net Current Asset Value |
593.34 | 575.27 | 521.06 | 478.91 | |
EV/EBIT |
0.31 | 0.47 | 0.89 | 0.92 | |
Capex to Sales |
0.06 | 0.01 | 0.80 | 0.42 | |
Net Profit Margin |
(503.66%) | (42.03%) | (6,857.38%) | (8,002.07%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
62.62 | 35.62 | 43.65 | 54.09 | |
Average Payables |
9.18 | 12.73 | 8.54 | 11.96 | |
Average Assets |
880.35 | 837.23 | 768.15 | 719.38 | |
Average Common Equity |
724.76 | 701.52 | 647.33 | 589.59 |
Columns are period end dates